UBS Group AG Raises Stock Position in Relay Therapeutics, Inc. $RLAY

UBS Group AG grew its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 94.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 296,017 shares of the company’s stock after purchasing an additional 143,764 shares during the period. UBS Group AG owned about 0.17% of Relay Therapeutics worth $2,504,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of RLAY. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Relay Therapeutics by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after purchasing an additional 1,757 shares during the period. Cresset Asset Management LLC lifted its holdings in shares of Relay Therapeutics by 5.0% during the third quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock worth $203,000 after purchasing an additional 1,848 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Relay Therapeutics by 8.1% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company’s stock worth $145,000 after purchasing an additional 2,079 shares during the period. Prelude Capital Management LLC lifted its holdings in shares of Relay Therapeutics by 18.7% during the third quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock worth $103,000 after purchasing an additional 3,100 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in shares of Relay Therapeutics by 17.8% during the third quarter. SG Americas Securities LLC now owns 31,945 shares of the company’s stock worth $167,000 after purchasing an additional 4,825 shares during the period. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a report on Wednesday, April 8th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Relay Therapeutics in a report on Tuesday, May 19th. Oppenheimer increased their price target on Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. HC Wainwright raised their target price on Relay Therapeutics from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. Finally, The Goldman Sachs Group raised their target price on Relay Therapeutics from $13.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.30.

Relay Therapeutics Stock Performance

Relay Therapeutics stock opened at $14.17 on Wednesday. Relay Therapeutics, Inc. has a one year low of $2.83 and a one year high of $17.32. The business has a fifty day moving average of $12.87 and a two-hundred day moving average of $9.85. The company has a market cap of $2.71 billion, a P/E ratio of -9.03 and a beta of 1.74.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.58 million. Sell-side analysts predict that Relay Therapeutics, Inc. will post -1.59 EPS for the current year.

Insider Buying and Selling

In other news, CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $12.86, for a total transaction of $227,840.62. Following the completion of the transaction, the chief financial officer owned 195,178 shares of the company’s stock, valued at $2,509,989.08. The trade was a 8.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 40,449 shares of company stock valued at $532,889 over the last three months. 5.04% of the stock is currently owned by company insiders.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.